Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Recommendation of “Buy” by Brokerages

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have been assigned a consensus recommendation of “Buy” from the eight research firms that are covering the stock, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $24.67.

A number of research firms have weighed in on STOK. HC Wainwright restated a “buy” rating and set a $47.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, March 18th. Finally, Chardan Capital reissued a “buy” rating and set a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday, March 19th.

Insider Transactions at Stoke Therapeutics

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 10,382 shares of Stoke Therapeutics stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the transaction, the director now directly owns 148,253 shares of the company’s stock, valued at $1,285,353.51. The trade was a 6.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Barry Ticho sold 3,884 shares of the business’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the completion of the transaction, the insider now owns 63,962 shares in the company, valued at $554,550.54. The trade was a 5.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 16,532 shares of company stock worth $143,332 in the last ninety days. Insiders own 11.30% of the company’s stock.

Institutional Trading of Stoke Therapeutics

Several institutional investors have recently made changes to their positions in STOK. Barclays PLC grew its position in Stoke Therapeutics by 145.3% in the third quarter. Barclays PLC now owns 79,740 shares of the company’s stock worth $980,000 after acquiring an additional 47,239 shares during the period. Geode Capital Management LLC grew its holdings in shares of Stoke Therapeutics by 9.7% during the 3rd quarter. Geode Capital Management LLC now owns 870,831 shares of the company’s stock worth $10,705,000 after purchasing an additional 76,661 shares during the period. State Street Corp grew its holdings in shares of Stoke Therapeutics by 8.6% during the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company’s stock worth $21,248,000 after purchasing an additional 137,145 shares during the period. RTW Investments LP increased its position in shares of Stoke Therapeutics by 10.1% during the 3rd quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock worth $57,177,000 after purchasing an additional 427,447 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in Stoke Therapeutics by 1,589.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company’s stock valued at $936,000 after buying an additional 71,647 shares during the period.

Stoke Therapeutics Stock Down 3.2 %

Shares of Stoke Therapeutics stock opened at $7.21 on Friday. The firm has a market cap of $389.90 million, a PE ratio of -3.43 and a beta of 0.99. Stoke Therapeutics has a twelve month low of $7.06 and a twelve month high of $17.58. The business has a 50-day moving average price of $9.32 and a 200 day moving average price of $11.19.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.38. The company had revenue of $22.61 million for the quarter, compared to analyst estimates of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. On average, sell-side analysts expect that Stoke Therapeutics will post -2.01 EPS for the current year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.